Ribo Submits European Clinical Trial Application for a Novel Dual Targeting siRNA SR122 for Mixed and Severe Dyslipidemia, Further Strengthening Its Footprint in the Area of Lipid Disorder

SUZHOU, China and MÖLNDAL, Sweden, Nov. 10, 2026 /PRNewswire/ — Suzhou Ribo Life Science (06938. HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as “Ribo”) announced the submission of a Phase Ⅰ Clinical Trial Application (CTA) in EU for SR122, a dual GalNAc. ..

Read full story on Pr Newswire Apac